Value of serum human epidermal growth factor receptor 2 (HER2)/ neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trials

Journal of Clinical Oncology

Volumn 27, Issue 36, 2009, Pages

  Ali, Suhail M ^a,b   Leitzel, Kim ^a,b   Lipton, Allan ^a,b   Carney, Walter P ^c   Köstler, Wolfgang J ^d  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b Lebanon VAMC   (United States)

^c Oncogene Science   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; MONOCLONAL ANTIBODY;

BLOOD SAMPLING; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG RESPONSE; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; BLOOD; BREAST TUMOR; ENZYMOLOGY; FEMALE; HUMAN; METHODOLOGY; NOTE; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMANS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2;

EID: 74949093236     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.4674     Document Type: Letter

References (2)

1. Lennon S, Barton C, Banken L, et al: Utility of serum HER2 extracellular domain assessment in clinical decision making: Pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol 27:1685-1693, 2009
2. Ali SM, Carney W, Esteva FJ, et al: Serum HER2/neu and relative resistance to trastuzumab-based therapy in metastatic breast cancer patients. Cancer 113:1294-1301, 2008